BARRETT HODGSON PAKISTAN

Company Type: Factory

Company Introduction:

Barrett Hodgson Pakistan (Pvt) Ltd. is a well-established pharmaceutical manufacturing company based in Pakistan. Founded in 1991, the company specializes in the production and marketing of a wide range of high-quality pharmaceutical products. It operates with a strong commitment to health and wellness, adhering to international quality standards in its manufacturing facilities to serve the healthcare needs of its customers.

Barrett Hodgson Pakistan (Pvt) Ltd manufactures and sells a diverse range of pharmaceutical products across various therapeutic areas. Their product portfolio includes antibiotics and anti-infectives for treating bacterial and other infections. They also offer cardiovascular agents for conditions related to the heart and blood vessels, such as hypertension and cholesterol management. Gastrointestinal products are available for digestive system disorders, including antacids, anti-ulcerants, and laxatives.

The company provides respiratory medications for conditions like asthma, bronchitis, and allergies, encompassing bronchodilators and antihistamines. Their range extends to central nervous system (CNS) drugs for neurological and psychiatric conditions, including pain relievers, anxiolytics, and antidepressants. Pain management and anti-inflammatory drugs, such as NSAIDs, are also a significant part of their offerings.

Furthermore, Barrett Hodgson Pakistan produces and distributes vitamins and nutritional supplements to address deficiencies and support general health. They also have a line of antidiabetic drugs for the management of diabetes and dermatological preparations, including topical creams and ointments for skin conditions. Their product list often includes various formulations of active ingredients such as Amoxicillin, Clavulanic Acid, Cefixime, Azithromycin, Diclofenac, Ibuprofen, Paracetamol, Omeprazole, Esomeprazole, Salbutamol, Metformin, Atorvastatin, and Alprazolam, among others, many of which are produced under licensing agreements.